A NEW TREATMENT DOES INCREASE BY 30% SURVIVAL IN PATIENTS WITH PANCREATIC CANCER
This is the largest study in pancreatic cancer developed in the last 20 years, a tumor for which little progress had been made in his tratamientoEl MPACT study analyzes a sample of 861 patients with metastatic pancreatic cancer and has involved eight hospitals españolesMás half of patients with pancreatic cancer are diagnosed when the disease has already spread. The average life expectancy in these cases is just 5 months
Madrid, October 17, 2013. It has taken nearly two decades to achieve a significant improvement in the treatment of pancreatic cancer, a tumor with very poor prognosis for which there has been little significant progress in recent times. Fortunately, data from the study MPACT (Metastatic Pancreatic Adenocarcinoma Clinical Trial) presented today in Madrid, show that adding a new drug to standard treatment achieved increasing the survival of people with advanced pancreatic cancer by 30 percent.
"This is the most important in pancreatic cancer developed in the last 20 years and the first study that really puts in the hands of doctors a drug that has a real and very conclusive in patient survival impact. It is an important study, "said Dr. Manuel Hidalgo, director of the Comprehensive Cancer Center Clara Campal (CIOCC) of HM hospitals in Madrid and one of the researchers who participated in the development of such work.
The MPACT is a phase III randomized clinical trial in patients with advanced pancreatic cancer with the main objective of increasing overall survival. "The goal was to demonstrate that the new treatment with nab-paclitaxel and gemcitabine improves survival versus gemcitabine alone, which was the classical treatment we used. The study shows that the risk of death decreased by 30% in patients receiving the experimental treatment compared to those receiving conventional treatment, which is an increase of great magnitude, "continues Dr. Hidalgo.
"Achieving improved overall survival is very important and also to change the current standard of care for these patients, opens the doors of pancreatic cancer research, both to better understand the biology of this type of cancer and the design studies in other stages of the disease and for analysis of biomarkers that help us better select patients, and for the design and evaluation of new molecules and drug combinations that lead us to overcome this serious disease " adds Dr. Carmen Guillen, Familial Cancer Unit of the University Hospital Ramon y Cajal in Madrid.
Developed between May 2009 and April 2012 were included in the study 861 patients from 161 different hospitals, 8 of them Spanish (Center Comprehensive Cancer Clara Campal (CIOCC) and hospitals October 12, Ramon y Cajal and Clinical San Carlos de Madrid, the Vall d'Hebron and the Clinic of Barcelona, the Virgen del Rocio in Seville and the Reina Sofia in Cordoba).
"The participation of Spanish researchers and centers as important as it demonstrates our ability to put ourselves in a first level research work on the development of new drugs to fight cancer international study," says Dr. Guillén.
Further evidence of the importance of these results is the recent publication of the data in the online edition of the prestigious medical journal The New England Journal of Medicine. "The publication of the MPACT trial in the NEJM shows that this is a study designed and conducted with methodological rigor excellent and that research results have great significance for the treatment of patients with advanced pancreatic cancer," explains Dr. Guillen.
Pancreatic cancer is the tenth tumor in prevalence but represents the fourth leading cause of cancer-related death in both Europe and the United States. In Spain about 5,000 cases a year of pancreatic cancer, of which 4,900 are diagnosed ending in death.
Moreover, over half of patients with pancreatic cancer are diagnosed when the disease has already spread. "Most diagnoses are made in advanced stages and in metastatic disease status, so the average life expectancy occurs when the diagnosis is only five months," concludes Dr. Fernando Rivera, of Oncology the Marqués de Valdecilla University Hospital of Santander.